Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis
- Author
- Eli Meltzer, Paul Ratner, Claus Bachert (UGent) , Warner Carr, William Berger, G Walter Canonica, James Hadley, Phil Lieberman, Frank C Hampel, Joaquim Mullol, Ullrich Munzel, David Price, Glenis Scadding, J Christian Virchow, Ulrich Wahn, Ruth Murray and Jean Bousquet
- Organization
- Keywords
- Azelastine, Allergic rhinitis, Fluticasone, MP29-02, Responder analysis, Severe chronic upper airway disease, FUROATE NASAL SPRAY, QUALITY-OF-LIFE, OCULAR SYMPTOMS, FLUTICASONE PROPIONATE, CONTROLLED-TRIAL, IMPACT, GUIDELINES, MANAGEMENT, BURDEN, IMPLEMENTATION
Downloads
-
(...).pdf
- full text
- |
- UGent only
- |
- |
- 219.38 KB
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-4290595
- MLA
- Meltzer, Eli, et al. “Clinically Relevant Effect of a New Intranasal Therapy (MP29-02) in Allergic Rhinitis Assessed by Responder Analysis.” INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, vol. 161, no. 4, 2013, pp. 369–77, doi:10.1159/000351404.
- APA
- Meltzer, E., Ratner, P., Bachert, C., Carr, W., Berger, W., Canonica, G. W., … Bousquet, J. (2013). Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis. INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 161(4), 369–377. https://doi.org/10.1159/000351404
- Chicago author-date
- Meltzer, Eli, Paul Ratner, Claus Bachert, Warner Carr, William Berger, G Walter Canonica, James Hadley, et al. 2013. “Clinically Relevant Effect of a New Intranasal Therapy (MP29-02) in Allergic Rhinitis Assessed by Responder Analysis.” INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY 161 (4): 369–77. https://doi.org/10.1159/000351404.
- Chicago author-date (all authors)
- Meltzer, Eli, Paul Ratner, Claus Bachert, Warner Carr, William Berger, G Walter Canonica, James Hadley, Phil Lieberman, Frank C Hampel, Joaquim Mullol, Ullrich Munzel, David Price, Glenis Scadding, J Christian Virchow, Ulrich Wahn, Ruth Murray, and Jean Bousquet. 2013. “Clinically Relevant Effect of a New Intranasal Therapy (MP29-02) in Allergic Rhinitis Assessed by Responder Analysis.” INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY 161 (4): 369–377. doi:10.1159/000351404.
- Vancouver
- 1.Meltzer E, Ratner P, Bachert C, Carr W, Berger W, Canonica GW, et al. Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis. INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY. 2013;161(4):369–77.
- IEEE
- [1]E. Meltzer et al., “Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis,” INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, vol. 161, no. 4, pp. 369–377, 2013.
@article{4290595, author = {{Meltzer, Eli and Ratner, Paul and Bachert, Claus and Carr, Warner and Berger, William and Canonica, G Walter and Hadley, James and Lieberman, Phil and Hampel, Frank C and Mullol, Joaquim and Munzel, Ullrich and Price, David and Scadding, Glenis and Virchow, J Christian and Wahn, Ulrich and Murray, Ruth and Bousquet, Jean}}, issn = {{1018-2438}}, journal = {{INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY}}, keywords = {{Azelastine,Allergic rhinitis,Fluticasone,MP29-02,Responder analysis,Severe chronic upper airway disease,FUROATE NASAL SPRAY,QUALITY-OF-LIFE,OCULAR SYMPTOMS,FLUTICASONE PROPIONATE,CONTROLLED-TRIAL,IMPACT,GUIDELINES,MANAGEMENT,BURDEN,IMPLEMENTATION}}, language = {{eng}}, number = {{4}}, pages = {{369--377}}, title = {{Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis}}, url = {{http://doi.org/10.1159/000351404}}, volume = {{161}}, year = {{2013}}, }
- Altmetric
- View in Altmetric
- Web of Science
- Times cited: